Provided by Tiger Trade Technology Pte. Ltd.

Immunic, Inc.

8.19
+0.63008.33%
Post-market: 8.03-0.1600-1.95%19:31 EDT
Volume:510.93K
Turnover:4.17M
Market Cap:111.38M
PE:-2.05
High:8.60
Open:7.63
Low:7.47
Close:7.56
52wk High:17.43
52wk Low:5.06
Shares:13.60M
Float Shares:12.01M
Volume Ratio:1.01
T/O Rate:4.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9979
EPS(LYR):-6.2414
ROE:-138.17%
ROA:-66.80%
PB:0.87
PE(LYR):-1.31

Loading ...

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)

TIPRANKS
·
Aug 12

Immunic Posts Investor Presentation Highlighting Vidofludimus Calcium Phase 3 MS Program

Reuters
·
Aug 11

Immunic Q2 Loss Per Share USD 0.80

THOMSON REUTERS
·
Aug 11

Immunic Q2 EPS $(0.80) Beats $(1.10) Estimate

Benzinga Earnings
·
Aug 11

Immunic reports Q2 EPS (80c), consensus ($1.16)

TIPRANKS
·
Aug 11

Immunic Q2 Net Loss Widens to $34.1 Million; Operating Expenses Rise to $35.3 Million

Reuters
·
Aug 11

Immunic Files Form 3 for Director Elena Ridloff, Reporting no Beneficial Ownership

Reuters
·
Aug 11

Top News Today/Canada: Barrick Settles Newmont Dispute, Clearing Way to List Its Gold Assets

Dow Jones
·
Aug 11

Immunic Appoints Elena Ridloff to Board of Directors

Reuters
·
Aug 11

Immunic Inc Expected to Post a Loss of $1.19 a Share - Earnings Preview

Reuters
·
Aug 03

Immunic Updates Corporate Strategy, Highlights Vidofludimus Plans

TIPRANKS
·
Jul 15

Immunic Publishes Investor Presentation Outlining Vidofludimus Calcium Phase 3 Program in Multiple Sclerosis

Reuters
·
Jul 14

Immunic Names CEO Erik Lundgren to Board After Tamar Howson Retirement Resignation

Reuters
·
Jul 07

Immunic Holds Annual Shareholder Meeting, Backs 6 Million-share Increase to Equity Plan

Reuters
·
Jun 30

Immunic joins H.C. Wainwright Neuro Perspectives Expert Summit fireside chat

Reuters
·
Jun 10

Immunic files Form 3 initial beneficial ownership statement for CEO Erik Lundgren

Reuters
·
Jun 02

Immunic publishes investor presentation on oral immunology pipeline led by vidofludimus calcium in multiple sclerosis

Reuters
·
Jun 01

Stifel Nicolaus Reaffirms Their Buy Rating on Immunic (IMUX)

TIPRANKS
·
May 29

Immunic presents new Phase 2 CALLIPER analyses of vidofludimus calcium in progressive multiple sclerosis at CMSC 2026

Reuters
·
May 28

Eqs-News: Immunic to Present Additional Phase 2 Calliper Trial Data for Vidofludimus Calcium at the Cmsc Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

THOMSON REUTERS
·
May 28